Clin2
NCT06746298Likely a fitNot yet recruiting

Rectal cancer treatment response study using gene testing

Rectal CancerNeoadjuvant Therapy

Part of Cancer, Digestive system clinical trials.

This study looks at how well rectal cancer responds to chemotherapy and radiation before surgery. It uses a genetic test on tumor tissue to predict whether the treatment will work for you.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
118 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 or older and male or cannot become pregnant.
  • You have rectal cancer confirmed by a biopsy.
  • You are planning to receive chemotherapy or radiation before surgery as recommended by your doctor.
  • You have tumor tissue from a biopsy that can be used for genetic testing.
  • You do not have any other type of cancer.
  • You agree to join the study and sign a consent form.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06637462Recruiting
Studying standard treatment response before rectal cancer surgery

This study looks at how rectal cancer responds to the usual chemotherapy and radiation given before surgery. It aims to learn if certain molecular features of your tumor can predict how well it responds to treatment.

Middletown, New Jersey
NCT06616870Not yet recruiting
Genetic and radiation markers for rectal cancer treatment

This study looks at how your genetic makeup and response to radiation might help predict how well you will respond to chemotherapy and radiation therapy given before surgery for locally advanced rectal cancer. It may help doctors better personalize your treatment plan.

Aviano, Pordenone
NCT03573791Recruiting
Testing markers to predict chemo-radiation response in rectal cancer

This trial studies lab “biomarkers” (measurable cancer features) to predict whether rectal cancer will resist chemo-radiation before surgery. The goal is to help doctors better choose treatments and avoid ineffective therapy.

Wuhan, Hubei
NCT06589388Recruiting
Using a blood test to predict rectal cancer treatment success

This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.

Ho Chi Minh City
NCT07188025Recruiting· Phase 3
Cancer DNA test to guide chemo after rectal cancer surgery

This trial tests whether checking for tumor DNA in your blood after surgery can help decide if you need additional chemotherapy. If the test finds cancer DNA, you may get chemo to lower the risk of the cancer coming back.

's-Hertogenbosch
NCT05943210Recruiting
Molecular testing of rectal cancer after short-course radiation

This study looks at molecular (tumor biology) features of rectal cancer in people receiving standard short-course radiation. Your tissue and/or samples may be used to better understand the cancer and how it responds to treatment.

Chicago, Illinois

Hear when a new Rectal Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.